文献速递急性肾损伤慢性肾脏病

可溶性鸟苷酸环化酶激活剂减轻缺血性肾损伤

Activating soluble guanylyl cyclase attenuates ischemic kidney damage.
PubMed 文献 · Kidney Int · 2024-11-19

该研究在大鼠单侧缺血再灌注损伤后口服sGC激活剂BAY 60-2770,评估其对微血管、血流、纤维化和炎症的影响。结果显示该治疗增加组织cGMP、扩张肾微血管、改善血流和氧合,减轻肾重量丢失、细胞损伤、纤维化和炎症,并显著改善血浆胱抑素C和肌酐,提示sGC激活可能保护肾脏并延缓AKI向CKD转化。

要点

  • sGC激活剂BAY 60-2770可扩张肾微血管并改善血流与氧合
  • 治疗减轻肾重量丢失、细胞损伤、纤维化和炎症
  • 血浆胱抑素C和肌酐显著改善提示肾功能恢复

核心结论

  • sGC激活可提供有效肾脏保护并延缓AKI向CKD转化。

研究设计与样本

  • 大鼠单侧缺血再灌注损伤模型,缺血后口服BAY 60-2770或溶媒。
  • 在术后第3、7、14天(急性期)和第84天(晚期)评估。
  • 体外用人肾小管细胞(HK-2)暴露于缺氧或TGF-β。

主要发现

  • 溶媒组髓质微血管变窄、皮质微血管呈肥厚性内向重构。
  • 急性损伤标志物Kim-1和Ngal mRNA在急性期升高、晚期下降。
  • 肾重量在急性期后下降,纤维化在第7天后开始。
  • 纤维化标志物Col1a、Tgf-β1和炎症标志物Il-6、Tnf-α持续升高,伴单核细胞浸润。
  • BAY 60-2770增加组织cGMP浓度,扩张肾微血管,改善血流和氧合。

关键数值与推荐

  • BAY 60-2770治疗显著减轻肾重量丢失、细胞损伤、纤维化和炎症。
  • 血浆胱抑素C和肌酐在sGC激活剂治疗下显著改善。
  • 不能排除未损伤肾的GFR升高超过肾脏储备的可能。

临床怎么用

  • sGC激活可能成为减轻缺血性肾损伤和延缓AKI-CKD转化的潜在策略。

局限性

  • 不能排除未损伤肾的GFR升高超过肾脏储备的可能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Can direct activation of soluble guanylyl cyclase (sGC) provide kidney-protection? To answer this, we tested the kidney-protective effects of a sGC activator, which functions independent of nitric oxide and with oxidized sGC, in an acute kidney injury (AKI) model with transition to chronic kidney disease (CKD). We hypothesize this treatment would provide protection of kidney microvasculature, kidney blood flow, fibrosis, inflammation, and kidney damage. Assessment took place on days three, seven, 14 (acute phase) and 84 (late phase) after unilateral ischemia reperfusion injury (IRI) in rats. Post-ischemia, animals received vehicle or the sGC activator BAY 60-2770 orally. In the vehicle group, medullary microvessels narrowed and cortical microvessels showed hypertrophic inward remodeling. The mRNA levels of acute injury markers (Kim-1, Ngal) were high in the acute phase but declined in the late phase. Kidney weight decreased after the acute phase, while fibrosis started after day seven. Abundance of fibrotic (Col1a, Tgf-β1) and inflammatory markers (Il-6, Tnf-α) remained elevated throughout, along with mononuclear cell invasion, with elevated plasma cystatin C and creatinine. BAY 60-2770 treatment increased tissue cGMP concentration, dilated kidney microvasculature, and enhanced blood flow and oxygenation. This intervention significantly attenuated kidney weight loss, cell damage, fibrosis, and inflammation. Plasma cystatin C and creatinine improved significantly with sGC activator treatment indicating functional recovery, though possible GFR increase above kidney reserve in uninjured kidneys could not be excluded. In cultured human tubular cells (HK-2 cells) exposed to hypoxia or profibrotic TGF-β, BAY 60-2770 improved abundance patterns of pathologically relevant genes. Overall, our results show that sGC activation may provide effective kidney-protection and attenuate the AKI-to-CKD transition.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Lichtenberger FB, Xu M, Erdoğan C, et al. Activating soluble guanylyl cyclase attenuates ischemic kidney damage. Kidney Int. 2024. PMID: 39571904. doi:10.1016/j.kint.2024.10.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。